Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of bimekizumab in moderate to severe hidradenitis suppurativa
2024-511035-10-00Phase 3Completed
- Sponsor
- UCB
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in hidradenitis suppurativa (HS), sponsored by UCB. Primary endpoint: Treatment-emergent adverse events. Started Aug 2024; status: completed.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-511035-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511035-10-00.